Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Scientists Discover an Erectile Dysfunction Drug Could Also Regenerate Muscle : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-10-17

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. One other point was not covered by the paper.

  • 3 supported
  • 1 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Three of five check out. One claim the study doesn't address.

  • 3 supported
  • 1 overstated
  • 1 not covered
Open claim evidence
3
Source paper

Source layer

The 3 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedResearchers from the University of Rome Foro Italico reported that tadalafil could also boost tissue regeneration and repair in muscles.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that tadalafil increased proliferation/survival and delayed terminal differentiation in murine C2C12 myoblasts, and that authors speculated about regenerative therapeutic implications. But the lead wording that it could boost tissue regeneration and repair “in muscles” generalizes beyond the demonstrated in-vitro cell-line outcomes; no actual muscle tissue repair, animal regeneration, or human outcome is shown. The story’s body caveats partly mitigate this, but the lead still outruns the paper evidence.

1

Study evidence

Prolonged tadalafil (1 µM, up to 7 days) significantly increased C2C12 cell proliferation and survival, reducing cell death at all time points.

“C2C12 cells were treated with 1 µM tadalafil for up to seven days, and analyzed for proliferation, viability, myogenesis activation”
2

Study evidence

Authors propose tadalafil as a potential adjuvant pharmacological therapy for muscle-wasting disorders based on in vitro effects on C2C12 myoblast proliferation, survival, and early myogenic marker expression.

“These findings suggest its potential use as an adjuvant pharmacological therapy in the treatment of muscle-wasting disorders.”
Claim 2 of 5Not coveredWhen a scratch was made in the cells, tadalafil made it close up faster.View evidenceHide evidence

Why this verdict

The supplied abstract-level paper profile does not report a scratch/wound-closure assay or faster scratch closure. This may be a full-text result, but it is not verifiable from the abstract-depth evidence provided.

1

Study evidence

Prolonged tadalafil (1 µM, up to 7 days) significantly increased C2C12 cell proliferation and survival, reducing cell death at all time points.

“C2C12 cells were treated with 1 µM tadalafil for up to seven days, and analyzed for proliferation, viability, myogenesis activation”
Claim 3 of 5SupportedIn mouse muscle precursor cells in the lab, tadalafil increased the number of cells ready to become muscle and reduced the number of dead cells.View evidenceHide evidence

Why this verdict

Supported at abstract depth. The paper profile reports an in-vitro C2C12 myoblast experiment in which prolonged 1 µM tadalafil significantly increased proliferation and survival and reduced cell death, with increased/maintained early myogenic markers consistent with a larger less-differentiated myogenic cell population.

1

Study evidence

Prolonged tadalafil (1 µM, up to 7 days) significantly increased C2C12 cell proliferation and survival, reducing cell death at all time points.

“C2C12 cells were treated with 1 µM tadalafil for up to seven days, and analyzed for proliferation, viability, myogenesis activation”
Claim 4 of 5SupportedCells treated with tadalafil were less likely to mature into actual muscle fibers after a week, which the researchers said may preserve a larger reserve of muscle stem cells.View evidenceHide evidence

Why this verdict

Supported at abstract depth. The profile states that tadalafil delayed terminal differentiation and reduced MHC-positive multinucleated myotubes after prolonged exposure, while maintaining higher Pax7 and Myf6 after seven days. The story’s interpretation that this may preserve a reserve of progenitor-like cells is appropriately hedged.

1

Study evidence

Prolonged tadalafil (1 µM, up to 7 days) significantly increased C2C12 cell proliferation and survival, reducing cell death at all time points.

“C2C12 cells were treated with 1 µM tadalafil for up to seven days, and analyzed for proliferation, viability, myogenesis activation”
Claim 5 of 5SupportedThe researchers said the findings suggest tadalafil might eventually be useful as an adjuvant therapy for muscle-wasting disorders, but that more in vivo research is needed and there may be anti-doping concerns.View evidenceHide evidence

Why this verdict

Supported as a speculative interpretation. The profile reports that the authors suggested potential adjuvant use for muscle-wasting disorders and raised anti-doping/performance-enhancement concerns, while making clear these are extrapolations from in-vitro C2C12 findings with no in-vivo or clinical validation.

1

Study evidence

Prolonged tadalafil (1 µM, up to 7 days) significantly increased C2C12 cell proliferation and survival, reducing cell death at all time points.

“C2C12 cells were treated with 1 µM tadalafil for up to seven days, and analyzed for proliferation, viability, myogenesis activation”
2

Study evidence

Authors propose tadalafil as a potential adjuvant pharmacological therapy for muscle-wasting disorders based on in vitro effects on C2C12 myoblast proliferation, survival, and early myogenic marker expression.

“These findings suggest its potential use as an adjuvant pharmacological therapy in the treatment of muscle-wasting disorders.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper reports altered myokine/regulatory signaling: IL6 and Sirt3 upregulation and myostatin and TGFβ downregulation.

    This secondary mechanistic/signaling element is present in the paper profile but is not mentioned in the story presentation.

    From In vitro C2C12 tadalafil time-course (1 µM, up to 7 days)

  • Generalisability is limited by the abstract-reported design: a single C2C12 cell line and a single reported tadalafil concentration of 1 µM, with no quantitative effect sizes or detailed statistics available at abstract depth.

    The story mentions the broad in-vitro mouse-cell limitation, but the supplied presentation does not reflect the single-cell-line/single-concentration constraint or the lack of quantitative effect-size/statistical detail, which limits assessment of robustness and magnitude.

    From In vitro C2C12 time-course (1 µM tadalafil up to 7 days); In vitro C2C12 tadalafil time-course (1 µM, up to 7 days)

5 things the story did carry across
  • The study’s direct evidence comes from an in-vitro murine C2C12 myoblast model, not from human participants or in-vivo muscle injury/regeneration experiments.
  • Tadalafil exposure increased C2C12 cell proliferation and survival and reduced cell death.
  • Tadalafil enhanced early myogenic markers and maintained a less-differentiated/progenitor-like state, including higher Pax7 and Myf6 after seven days.
  • Tadalafil delayed terminal myogenic differentiation, reducing MHC-positive multinucleated myotubes.
  • The translational therapy and anti-doping points are interpretive extrapolations from cell-culture findings, not demonstrated clinical or athletic performance effects.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroDetermine how prolonged tadalafil exposure affects C2C12 myoblast proliferation, viability/survival, and progression through myogenesis (early markers vs terminal differentiation).In vitro C2C12 time-course (1 µM tadalafil up to 7 days)Expand

In plain English

In an in vitro C2C12 myoblast time-course, treatment with 1 µM tadalafil for up to seven days increased cell proliferation and survival, upregulated early myogenic markers while delaying terminal myogenic differentiation (fewer MHC-positive multinucleated myotubes), and altered expression of regulators/myokines (increased Sirt3 and IL6; decreased myostatin and TGFβ).

Key findings

  • Prolonged tadalafil (1 µM, up to 7 days) significantly increased C2C12 cell proliferation and survival, reducing cell death at all time points.
  • Tadalafil enhanced expression of early myogenic factors and maintained higher Pax7 and Myf6 expression after seven days, consistent with a less-differentiated phenotype.
“C2C12 cells were treated with 1 µM tadalafil for up to seven days, and analyzed for proliferation, viability, myogenesis activation”
What this piece can’t prove
  • Evidence is from an abstract-only summary of a single in vitro study (C2C12 cell line).

2 further details could not be confirmed from the summary.

2in vitroAssess whether prolonged tadalafil exposure alters myokine/cytokine release and associated regulatory signaling markers (e.g., IL6, Sirt3, myostatin, TGFβ) in C2C12 cells during myogenic progression.In vitro C2C12 tadalafil time-course (1 µM, up to 7 days)Expand

In plain English

In C2C12 myoblasts treated with 1 µM tadalafil for up to seven days, the authors report altered myokine/regulatory signaling: IL6 and Sirt3 were upregulated, while myostatin and TGFβ were downregulated. These marker changes accompanied a more proliferative, less differentiated phenotype.

Key findings

  • Prolonged (up to 7 days) exposure of C2C12 cells to 1 µM tadalafil was reported to upregulate IL6 and Sirt3.
  • Prolonged tadalafil exposure was reported to downregulate myostatin and TGFβ in C2C12 cells.
“and analyzed for ... myokine release”
What this piece can’t prove

3 further details could not be confirmed from the summary.

3otherDiscuss potential translational implications (adjuvant therapy for muscle-wasting disorders) and potential misuse in sport (anti-doping concern).Narrative interpretation/extrapolation from in vitro findingsExpand

In plain English

The authors interpret their in vitro C2C12 myoblast findings to propose that prolonged tadalafil exposure could serve as an adjuvant therapy for muscle-wasting disorders and simultaneously raise concerns about potential misuse as a performance-enhancing drug in sport. These statements are presented as extrapolations from cell-culture results, with no new human or animal data reported to support translational or regulatory claims.

Key findings

  • Authors propose tadalafil as a potential adjuvant pharmacological therapy for muscle-wasting disorders based on in vitro effects on C2C12 myoblast proliferation, survival, and early myogenic marker expression.
  • Authors raise concerns that tadalafil's effects on muscle regenerative machinery could be misused as a performance-enhancing drug in sport and call for evaluation by anti-doping agencies.
“These findings suggest its potential use as an adjuvant pharmacological therapy in the treatment of muscle-wasting disorders.”
What this piece can’t prove
  • Implications derive solely from in vitro C2C12 experiments; no new human or animal data are presented to support translational or anti-doping claims.
  • Extrapolation to clinical benefit or misuse in sport is speculative and requires preclinical and clinical validation.
  • Discussion does not address dosing, pharmacokinetics, safety, or regulatory considerations necessary for therapeutic or anti-doping conclusions.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 17 candidate papers

And 11 more candidates considered.